CN114984063B - Skin external composition and functional food composition - Google Patents
Skin external composition and functional food composition Download PDFInfo
- Publication number
- CN114984063B CN114984063B CN202210155151.9A CN202210155151A CN114984063B CN 114984063 B CN114984063 B CN 114984063B CN 202210155151 A CN202210155151 A CN 202210155151A CN 114984063 B CN114984063 B CN 114984063B
- Authority
- CN
- China
- Prior art keywords
- skin
- external
- composition
- rhodochrous
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 235000013376 functional food Nutrition 0.000 title claims abstract description 13
- 241000195493 Cryptophyta Species 0.000 claims abstract description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims description 40
- 230000008591 skin barrier function Effects 0.000 claims description 31
- 239000002552 dosage form Substances 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000469 ethanolic extract Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 241001204967 Martensia jejuensis Species 0.000 claims description 5
- 244000005714 skin microbiome Species 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 230000029305 taxis Effects 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 48
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 244000005700 microbiome Species 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 241000191963 Staphylococcus epidermidis Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000304 virulence factor Substances 0.000 description 6
- 230000007923 virulence factor Effects 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 241000168525 Haematococcus Species 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000005808 skin problem Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000187693 Rhodococcus rhodochrous Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- -1 silk fibroin Chemical compound 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101710145796 Staphylokinase Proteins 0.000 description 2
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 101150035844 clfB gene Proteins 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 101100227488 Staphylococcus aureus (strain USA300) fnbB gene Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 101150098467 fnbA gene Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 101150024289 hly gene Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 101150065015 spa gene Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a skin external composition and a functional food composition comprising an extract of red net algae as an active ingredient.
Description
Technical Field
The present invention relates to a skin external composition and a functional food composition.
Background
The skin barrier (skin barrier) is the outermost stratum corneum of the skin and may be referred to as the initial protective membrane of the skin. The skin barrier is composed of keratinocytes, and keratinocyte interstitium composed of lipids such as ceramide and proteins such as silk fibroin, etc., which form a multi-layered structure, thereby exerting a complete skin barrier effect. The primary function of the skin barrier is to prevent body fluid loss, toxin attack and pathogen invasion. Thus, damage to the skin barrier is not only due to purely mechanical damage to the top layer of the skin, but also may be caused by severe immune responses caused by invasion of various pathogenic bacteria. The limitation of antibiotic therapy, which is one of the existing treatments, is that it not only inhibits skin harmful bacteria (e.g., staphylococcus aureus Staphylococcus aureus), but also inhibits skin beneficial bacteria (e.g., staphylococcus epidermidis Staphylococcus epidermidis) as well, and thus its effect is not obvious. Therefore, there is an urgent need to develop a material that does not inhibit skin commensal beneficial bacteria but only harmful bacteria to improve skin barrier function.
Microbiome (microbiome) is a term synthesized from a microbiota (microbiota) representing a community of microorganisms and a genome (genome) representing the entire set of genes. The term microbiota is focused on the microbial strain itself, as opposed to the microbiome, which refers to a microorganism that inhabits the human body and has a symbiotic relationship, whereas microbiome refers to studies and techniques that deviate from existing individual microbiological analysis studies, genomics-based interactions between host organisms and microorganisms. It is well known that maintaining microbiome balance affects human function. Recently, a great deal of research is being conducted on skin microbiome and skin barrier in the fields of cosmetics, medicine, pharmacy, and based thereon, cosmetics, skin external preparations, and the like are actively developed.
Disclosure of Invention
Problems to be solved by the invention
One embodiment provides a skin external agent composition that does not inhibit skin symbiotic beneficial bacteria but only harmful bacteria to improve skin barrier function.
Another embodiment provides a functional food composition that does not inhibit skin commensal beneficial bacteria but only harmful bacteria to improve skin barrier function.
Solution for solving the problem
One embodiment provides a skin external composition comprising an extract of red net algae in ataxia as an active ingredient.
The concentration of the rhodochrous extract may be 12.5 μg/ml to 200 μg/ml.
The skin external composition can be used for preventing skin barrier damage.
The red net algae extract may be included in an amount of 0.001 to 10 wt% with respect to the total weight of the skin external composition.
The rhodochrous taxis extract can alleviate the toxicity of staphylococcus aureus (Staphylococcus aureus).
The extract of red net algae can maintain skin microbiome balance.
The extract of red net algae may be extracted with water, organic solvent or their mixture.
The organic solvent can be more than one selected from anhydrous or hydrous ethanol, glycerol, propylene glycol, butanediol, ethyl acetate, hexane and chloroform of C1-C4.
The skin external composition may be prepared in a dosage form selected from the group consisting of a astringent, a gel, a water-soluble liquid, a cream, a powder, an oil-in-water (O/W) type, and a water-in-oil (W/O) type. The skin external composition may be a cosmetic composition.
The skin external composition may be a pharmaceutical external composition for improving skin barrier function.
Another embodiment provides a functional food composition for improving skin barrier function comprising an extract of Haematococcus rhodochrous (Martensia jejuensis) as an active ingredient.
Effects of the invention
The skin external composition according to an embodiment prevents skin cell damage and maintains skin microbiome balance, thereby being effective in preventing skin barrier damage.
Particularly, it is effective against Staphylococcus aureus, and is effective against various diseases such as skin of allergic patients, and skin injury due to Staphylococcus aureus can be largely prevented in a skin barrier (skin barrier) injury state, and is effective against skin diseases such as allergic diseases.
In addition, the cosmetic composition contains a natural substance as an active ingredient, and thus side effects or risks caused by a synthetic substance are small.
Drawings
FIG. 1 is a graph showing the extent of inhibition of hemolytic activity of Staphylococcus aureus by an extract of Rhodococcus rhodochrous according to one embodiment.
Fig. 2 is a graph showing the ratio of staphylococcus epidermidis (s. Epididitis) to staphylococcus aureus (s. Aureus) in experimental and untreated control groups treated with rhodochrous extract according to an embodiment.
Fig. 3 is a graph showing the virulence factor-related gene expression levels of staphylococcus aureus at different concentrations of rhodochrous extract according to one embodiment.
Fig. 4 is a graph comparing the extent to which staphylococcus aureus in an experimental group treated with rhodochrous extract according to one embodiment caused skin cell apoptosis with an untreated control group.
Detailed Description
The present invention is described in more detail below. However, this is only to be specifically described for aiding in the understanding of the present invention, the scope of which is to be construed on the basis of the claims.
The skin external composition according to one embodiment comprises an extract of red net algae of Jizhou as an active ingredient.
The rhodochrous jizhou extract can be obtained by extracting rhodochrous jizhou. The rhodochrous jizhou (Martensia jejuensis) is a korean specific species belonging to the original jizhou sea area of the order rhodochrous jizhou dish.
The concentration of the rhodochrous extract may be 12.5 μg/ml to 200 μg/ml, for example, 25 μg/ml to 200 μg/ml, 50 μg/ml to 200 μg/ml, 100 μg/ml to 200 μg/ml. When the concentration of the extract of rhodochrous in Jizhou is within the above range, skin damage caused by staphylococcus aureus can be largely prevented in a state where the skin barrier is damaged.
The red net algae extract may be included in an amount of 0.001 to 10.0 wt%, for example, 0.01 to 0.2 wt%, with respect to the total weight of the skin external composition.
If the content is less than 0.001 wt%, an effective effect cannot be exhibited, and if it exceeds 10.0 wt%, there is a problem in the stability of the dosage form such as discoloration, odor change, etc.
The extract of Haematococcus rhodochrous can relieve toxicity of Staphylococcus aureus (Staphylococcus aureus) and improve skin barrier function.
Staphylococcus aureus (Staphylococcus aureus) is present on the surface of human skin and in pores. Staphylococcus residing generally on the skin does not cause disease in normal individuals, but staphylococcus aureus causes disease even in normal individuals. In particular, invasion into the body through a wound site is often associated with morbidity. The virulence factors (virulence factor) of staphylococcus aureus are roughly classified into virulence factors, exotoxins (exotoxins) and enzymes (enzymes) present in cells. Toxic factors present in cells include protein a, fibronectin binding factors, teichoic acid, and the like. Examples of the external toxins include enterotoxin, toxic shock syndrome toxin-1 (TSST-1), and alpha-hemolysin (Hla), and examples of the enzymes include plasma clotting enzyme (coagulase), staphylokinase (staphylokinase), protease (protease), deoxyribonuclease (DNase), and lipase (lipase) (microbiology department). Staphylococcus aureus with the characteristics plays a pathogenic role, and causes various epidermic infections such as abscess, food poisoning, pneumonia, meningitis, septicemia and the like. A variety of diseases such as skin of allergic patients are known, and staphylococcus aureus forms a colony (coloney) and a biofilm sufficiently in a state of skin barrier (skin barrier) damage, whereby inflammatory reaction and skin cell damage caused thereby further exacerbate symptoms. The result is a different distribution of skin microorganisms for those with normal skin barriers than those without.
The inventors of the present invention have found that rhodochrous extract is effective in improving skin barrier function, particularly in inhibiting staphylococcus aureus. Thus, the composition according to an embodiment can more effectively improve and maintain the skin barrier function for the skin damaged or weakened especially due to skin diseases, and has effects of enhancing skin moisturizing ability, preventing skin problems and preventing skin aging.
In addition, the rhodochrous state extract can maintain skin microbiome balance, thereby improving skin barrier function.
The rhodochrous extract may be extracted using water, an organic solvent or a mixed solvent thereof by a commonly used extraction method well known in the industry, for example, an organic solvent may be used.
The organic solvent may be one or more selected from the group consisting of C1-C4 anhydrous or hydrous ethanol, glycerol, propylene glycol, butylene glycol, ethyl acetate, hexane, and chloroform.
For example, an ethanol extract of the rhodochrous jetlag may be used.
The extract may be obtained by cold extraction, warm extraction or hot extraction, and commonly used extraction equipment, ultrasonic pulverizing extractor or fractionator may be used.
The prepared extract may be freed from the solvent by filtration, which may be, in particular, a filter paper or a reduced pressure filter, or concentration, which may be a reduced pressure concentrator, for example, a rotary evaporator, or drying, which may be, for example, performed by freeze-drying.
The skin external composition may contain various components in addition to the extract of red net algae in Jizhou, according to the method of use and purpose of use.
The skin external composition may be prepared into one or more dosage forms selected from the group consisting of skin lotion, emulsion, cream and powder, but is not limited thereto.
Specifically, the skin external composition may be prepared in a dosage form selected from the group consisting of a astringent, a gel, a water-soluble liquid, a cream, a powder, an oil-in-water (O/W) type, and a water-in-oil (W/O) type.
The skin external composition according to an embodiment may be used as a cosmetic composition. The skin care product is composed of natural substances, does not cause skin problems even if used frequently, can continuously improve the skin barrier function, and has the effects of moisturizing skin, improving wrinkles, preventing aging and the like. The cosmetic composition is not limited to any formulation conventionally prepared in the art, and may be prepared, for example, but not limited to, as a solution, suspension, emulsion, paste, gel, cream, emulsion, powder, soap, surfactant-containing cleaner, oil, powder foundation, emulsion foundation, wax foundation, spray, and the like. In more detail, it can be suitably used for preparing functional cosmetics such as foundation cosmetics of astringent, nourishing cream, moisturizing cream, essence, eye cream, lotion, mask and essence. On the other hand, the ingredients contained in the cosmetic composition of an embodiment may contain ingredients commonly used in cosmetic compositions, for example, usual adjuvants and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, in addition to the rhodochrous extract as an active ingredient.
The skin external composition according to an embodiment may be used as a pharmaceutical external composition for improving skin barrier function. As with the cosmetic composition described above, the pharmaceutical composition may have one or more uses selected from the group consisting of enhancing skin moisturization, preventing skin problems, and preventing skin aging.
The term "pharmaceutical composition" as used herein means an article having a slight effect on a pharmaceutical product among articles for the purpose of diagnosing, treating, ameliorating, reducing, disposing or preventing a human or animal disease, for example, according to the pharmaceutical laws, the term "pharmaceutical composition" means an article other than articles for use as a pharmaceutical product, and includes articles for the treatment or prevention of a human or animal disease, articles having a slight or indirect effect on a human body, and the like.
The pharmaceutical composition for external use is used for the purpose of improving skin barrier function, and more specifically, for the purpose of enhancing skin moisturization, preventing skin problems and preventing skin aging, and its dosage form is not particularly limited, and may be, for example, a composition in the form of a skin softening lotion, a nourishing lotion, a massage cream, a nourishing cream, a dressing, a mask, a sheet pack, a gel or a skin-adhering cosmetic dosage form, or a composition in the form of a transdermal administration dosage form such as a lotion, an ointment, a gel, a cream, a patch or a spray.
On the other hand, the pharmaceutical composition may be formulated with, in addition to the extract of red net algae, conventional adjuvants and carriers such as thickening agents, stabilizers, solubilizers, vitamins, pigments and fragrances, and the like, as required.
According to another embodiment, a functional food composition for improving skin barrier function is provided comprising an extract of rhodochrous (Martensia jejuensis) as an active ingredient. The functional food may include a health functional food. As with the cosmetic compositions described above, the functional food composition may also have one or more uses selected from the group consisting of enhancing skin moisturization, preventing skin problems, and preventing skin aging.
The kind of the functional food is not particularly limited, and for example, meat, sausage, bread, chocolate, candy, snack, pizza, stretched noodles, chewing gum, dairy products, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complex agents, and the like can be used, and all foods can be included in a broad sense.
The functional food composition may contain commonly used ingredients in addition to the rhodochrous extract, for example, nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerol, ethanol, carbonating agents used in carbonated beverages, or combinations thereof.
The following will illustrate examples and embodiments for the purpose of explaining the present invention in detail. However, the experimental examples of the present invention may be modified into various different forms, and it should not be construed that the scope of the present invention is limited to the experimental examples and examples described in detail below. Experimental examples and embodiments of the present invention serve to more fully illustrate the invention to one of ordinary skill in the art.
Preparation example 1: preparation of extract of red net algae
The dried whole strain of rhodochrous, jizhou, was crushed, immersed in 2 times of 95% ethanol, and exposed to an ultrasonic device (150 w, 30 ℃) for 30 minutes. After 24 hours of maceration, the extract was filtered through filter paper, and then the solvent was removed using a rotary vacuum concentrator, thereby preparing the rhodochrous macrocarpa extract.
Experimental example 1: strains, cell lines and culture conditions
The strain was cultured in pancreatin soybean broth (TSB) at a temperature of 37 ℃ and used for experiments using staphylococcus aureus (s. Aureus, ATCC 6538) as a skin pest and staphylococcus epidermidis (ATCC 12228) as a beneficial.
The skin keratinocyte HaCaT cells are added with 1Antibiotic-free DMEM medium with 0% FBS at 37deg.C, 5% CO 2 And used for experiments.
Experimental example 2: measurement of the extent of inhibition of hemolytic Activity
To measure the extent of inhibition of hemolytic activity of the rhodochrous extract against staphylococcus aureus, a hemolysis assay (haemolytisis assay) was performed using rabbit blood.
Before toxicity related experiments of staphylococcus aureus related to the rhodochrous extract are carried out, the Minimum Inhibitory Concentration (MIC) of the rhodochrous extract to the staphylococcus aureus is more than 2 mg/mul through previous experiments.
In Staphylococcus aureus 1X10 6 In CFU/ml, the culture was performed in TSB medium for 24 hours at a concentration of 100. Mu.g/ml, 50. Mu.g/ml, 25. Mu.g/ml of extract of Rhodophyllum jizhou. The cultured bacterial liquid was centrifuged, and only the supernatant was collected and filtered through a 0.2 μm needle filter for use in the experiment.
Mu.l of rabbit blood washed 3 times with PBS and 975. Mu.l of bacterial culture supernatant were added to 1.5ml of microtubes, and after incubation at 37℃for 1 hour, centrifugation was carried out at 5500g (gravitational acceleration) for 1 minute to obtain 200. Mu.l of supernatant, which was transferred to a microplate and absorbance was measured at 540nm with an enzyme-labeled instrument.
As shown in FIG. 1, in the experimental group treated with the extract of Rhodococcus rhodochrous of an example, it was confirmed that the hemolytic activity of the Staphylococcus aureus culture broth was inhibited.
Experimental example 3: evaluation of skin microbial Regulation efficacy
Staphylococcus aureus (S.aureus) and Staphylococcus epidermidis (S.epidermidis) cultured in TSB for 24 hours were each approximately 1X10 6 CFU/mL was inoculated into the new medium and incubated with 200. Mu.g/mL of the extract of Haematococcus rhodochrous for 24 hours. Then, it will be diluted 10 7 The double culture was applied to TSA and the number of colonies (colly) of Staphylococcus aureus and Staphylococcus epidermidis was counted.
As a result, as shown in fig. 2, it was confirmed that the ratio of staphylococcus epidermidis, which is a beneficial bacterium, was increased and the ratio of staphylococcus aureus, which is a harmful bacterium, was decreased in the experimental group treated with the rhodochrous taxis extract of one example, compared to the untreated control group.
Experimental example 4: staphylococcus aureus virulence factor expression
Real-time PCR experiments were performed to confirm the mRNA expression inhibition effect of the toxic factors of Staphylococcus aureus, namely, alpha-hemolysin (Hla), coagulation factors A/B (ClfA, clfB), fibronectin binding factors A/B (FnbA, fnbB), protein A (SpA), sortase (SrtA) genes.
In Staphylococcus aureus about 1x10 6 In CFU/ml, treatment was performed at 200. Mu.g/ml, 100. Mu.g/. Mu.l, 50. Mu.g/. Mu.l of extract concentration of Haematococcus rhodochrous followed by incubation for 24 hours. After 24 hours colonies were recovered and RNA was extracted (TE buffer, boiling at 100 ℃). After measuring the concentration and purity of the extracted RNA, 1. Mu.g of RNA was used to synthesize cDNA using a cDNA synthesis kit (Intron), and then real-time PCR was performed using SYBR Green.
As a result, as shown in FIG. 3, it was confirmed that the mRNA expression of the virulence factor Hla, clfB, fnbA/B, spA gene of Staphylococcus aureus was reduced in the Experimental group treated with the extract of Rhodococcus rhodochrous in economical state as compared with the control group treated with the extract of Rhodococcus rhodochrous in uneconomical state.
Experimental example 5: skin keratinocyte protective effect
Co-culture of skin keratinocytes (HaCaT) with Staphylococcus aureus was performed to confirm the skin cytoprotective effect based on the extract of Haematococcus rhodochrous.
Skin keratinocytes were cultured in 24-well plates until 80% of the basal surface was filled, staphylococcus aureus treatments were performed at about 1000 CFU/well, and after a given time of co-culture (co-culture), MTT experiments were performed to measure cell viability.
As a result, as shown in fig. 4, it was confirmed that apoptosis occurred in the skin keratinocytes (k+s) treated with staphylococcus aureus compared with the skin keratinocytes (K) not treated with staphylococcus aureus, and that apoptosis by staphylococcus aureus was inhibited in the group treated with red net algae extract.
From the above experimental results, it was confirmed that the rhodochrous state extract according to an embodiment is a natural material having an effect of preventing skin barrier damage by regulating toxicity of staphylococcus aureus.
The following shows various dosage forms prepared by using the extract of red net algae in Jizhou according to the results of the above experimental examples. However, it will be understood by those of ordinary skill in the art that these dosage form examples are merely illustrative of the present invention, and the dosage form of the present invention is not limited to these dosage form examples.
( Dosage form examples 1 to 3: cosmetic composition containing extract of red net algae of Jizhou province )
Dosage form example 1: emulsion (emulgion)
[ Table 1 ]
| Component name | Examples (wt%) |
| Stearic acid | 0.5 |
| Ethanol | 10.0 |
| Vaseline | 1.0 |
| Squalane (Squalene) | 2.5 |
| Liquid paraffin | 6.0 |
| Polyoxyethylene sorbitan monooleate | 1.5 |
| 1, 3-butanediol | 8.0 |
| Triethanolamine salt | 0.05 |
| Spice | 0.2 |
| Preservative agent | Proper amount of |
| Antioxidant agent | Proper amount of |
| Extract of red net algae | 0.05 |
| Purified water | To 100 |
Dosage form example 2: skin softening water (skin tone)
[ Table 2 ]
| Component name | Weight percent |
| Glycerol | 5.0 |
| 1, 3-butanediol | 3.0 |
| Ethanol | 5.0 |
| Polyoxyethylene nonylphenyl ether | 0.5 |
| Spice | Proper amount of |
| Preservative agent | Proper amount of |
| Extract of red net algae | 0.05 |
| Purified water | To 100 |
Dosage form example 3: cream (stream)
[ Table 3 ]
Claims (10)
1. A skin external composition contains ethanol extract of red net algae (Martensia jejuensis) as effective component.
2. The external skin preparation composition according to claim 1, wherein,
the concentration of the ethanol extract of the rhodochrous jizhou isTo->
3. The external skin preparation composition according to claim 1, wherein,
the skin external composition is used for preventing skin barrier damage.
4. The external skin preparation composition according to claim 1, wherein,
an ethanol extract comprising 0.001 wt% to 10 wt% of the rhodochrous jeorum, relative to the total weight of the skin external composition.
5. The external skin preparation composition according to claim 1, wherein,
the ethanol extract of rhodochrous taxis alleviates the toxicity of staphylococcus aureus (Staphylococcus aureus).
6. The external skin preparation composition according to claim 1, wherein,
the ethanol extract of rhodochrous state maintains skin microbiome balance.
7. The external skin preparation composition according to claim 1, wherein,
the skin external composition is prepared into a dosage form selected from the group consisting of a astringent, a gel, a water-soluble liquid, a cream, a powder, an oil-in-water dosage form, and a water-in-oil dosage form.
8. The skin external composition according to any one of claims 1 to 7, wherein,
the skin external composition is a cosmetic composition.
9. The skin external composition according to any one of claims 1 to 7, wherein,
the skin external composition is a pharmaceutical external composition for improving skin barrier function.
10. A functional food composition for improving skin barrier function comprises ethanol extract of red net algae (Martensia jejuensis) as effective component.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210027448A KR102293592B1 (en) | 2021-03-02 | 2021-03-02 | Skin external composition comprising extract of Martensia jejuensis and functional food comprising extract of Martensia jejuensis |
| KR10-2021-0027448 | 2021-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114984063A CN114984063A (en) | 2022-09-02 |
| CN114984063B true CN114984063B (en) | 2023-12-15 |
Family
ID=77465654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210155151.9A Active CN114984063B (en) | 2021-03-02 | 2022-02-21 | Skin external composition and functional food composition |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102293592B1 (en) |
| CN (1) | CN114984063B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102605534B1 (en) * | 2022-08-03 | 2023-11-24 | 박헌의 | Snail feed composition with wild ginseng root culture media |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105325460A (en) * | 2010-02-25 | 2016-02-17 | 马罗内生物创新公司 | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom |
| WO2018216744A1 (en) * | 2017-05-23 | 2018-11-29 | 一丸ファルコス株式会社 | Cosmetic and skin protecting agent containing lactic acid bacterium |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101510936B1 (en) * | 2013-01-29 | 2015-04-10 | 제주대학교 산학협력단 | Composition comprising extract of Martensia bibarii for prevention and treatment of autoimmune disease or inflammatory disease |
-
2021
- 2021-03-02 KR KR1020210027448A patent/KR102293592B1/en active IP Right Grant
-
2022
- 2022-02-21 CN CN202210155151.9A patent/CN114984063B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105325460A (en) * | 2010-02-25 | 2016-02-17 | 马罗内生物创新公司 | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom |
| WO2018216744A1 (en) * | 2017-05-23 | 2018-11-29 | 一丸ファルコス株式会社 | Cosmetic and skin protecting agent containing lactic acid bacterium |
Non-Patent Citations (3)
| Title |
|---|
| DNA barcoding of the funoran-producing red algal genus Gloiopeltis (Gigartinales) and description of a new species, Gloiopeltis frutex sp. nov.;Mi Yeon Yang 等;J Appl Phycol;1381–1392 * |
| Reappraisal of nine species of Martensia (Delesseriaceae, Rhodophyta) reported from Korea based on morphology and molecular analyses;Jeong Chan Kang 等;Botanica Marina;第58卷(第3期);151–166 * |
| 中国海洋红藻门新分类***;丁兰平 等;广西科学;第22卷(第2期);１６４-１８８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102293592B1 (en) | 2021-08-26 |
| CN114984063A (en) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102293593B1 (en) | Skin external composition comprising Asparagopsis taxiformis extract and functional food comprising extract of Asparagopsis taxiformis extract | |
| CN105451751B (en) | Composition for removing skin cutin material containing green tea lactobacillus | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR20110134151A (en) | Agent for treating or preventing skin inflammatory disease comprising cultures of mixed bacteria, cosmetic composition, and pharmaceutical composition | |
| CN114984063B (en) | Skin external composition and functional food composition | |
| KR102623439B1 (en) | Anti-fungal composition comprising lactobacillus plantarum | |
| KR102286991B1 (en) | Cosmetic composition for regulating microbe in skin comprising extract of zanthoxylum piperitum fruit or fractions from thereof | |
| CN116077415B (en) | Ternary probiotic factor composition for regulating skin microecological balance | |
| KR101433823B1 (en) | External Composition for Skin Using an Extract or a Fraction of Padina arborescens | |
| KR102031359B1 (en) | Composition for improving microbial flora containing extract of Rosae Multiflorae fructus | |
| KR102485257B1 (en) | Composition comprising lactic acid bacteria derived from camellia japonica for caring damages of skin cells by microdust | |
| KR102139000B1 (en) | Antioxidant, anti-wrinkle, whitening and antibiotic cosmetic composition comprising fermented Methyl Sulfonyl methane extract and the preparation method of the same | |
| KR101914568B1 (en) | Cosmetic Composition For A Alleviating Atopic Dermatitis And Pruritis Using By Bioconversion Of The Extracts and Method For Manufacturing the same | |
| KR102031354B1 (en) | Composition for improving microbial flora containing extract of cinnamomi ramulus | |
| KR102492106B1 (en) | Cosmetic composition | |
| KR102244812B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus plantarum subsp. plantarum SDCM 1002 and Saccharomyce cerevisiae SDCM 3017, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| CN114561331B (en) | Lactobacillus paracasei and application thereof | |
| KR102194314B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising green tea fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR102180666B1 (en) | Cosmetic Composition for Skin Care Containing Fermented Extracts of Applemint, Citron and Sparassis Crispa | |
| KR102031361B1 (en) | Composition for improving microbial flora containing extract of Lepidii seu Descurainiae semen | |
| KR102031355B1 (en) | Composition for improving microbial flora containing extract of Angelica gigas root | |
| KR102031356B1 (en) | Composition for improving microbial flora containing extract of jujube | |
| KR102031353B1 (en) | Composition for improving microbial flora containing extract of castaneae semen | |
| KR102031362B1 (en) | Composition for improving microbial flora containing extract of Allii Fistulosi bulbus | |
| US20220031603A1 (en) | Composition for improving microflora containing herbal medicine extract as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |